ProQR Therapeutics (PRQR)
(Delayed Data from NSDQ)
$2.14 USD
+0.02 (0.94%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $2.16 +0.02 (0.93%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.14 USD
+0.02 (0.94%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $2.16 +0.02 (0.93%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Zacks News
Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of 15.79% and 9.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Regenxbio (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of 11.11% and 5.18%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GSK (GSK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 15.96% and 3.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -3.51% and 28.60%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Is ProQR (PRQR) Stock a Solid Choice Right Now?
by Zacks Equity Research
ProQR (PRQR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 2.13% and 22.98%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of -11.11% and 7.23%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of 26.32% and 54.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ProQR (PRQR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of 0% and 75.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of -23.08% and 6.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -4.55% and 33.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will ProQR (PRQR) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More
by Zacks Equity Research
Updates from Gilead Sciences (GILD) and ProQR (PRQR) are the key highlights from the biotech sector during the past week.
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly
by Zacks Equity Research
ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.
ProQR (PRQR) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of -47.83% and 7.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ProQR (PRQR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of 15.38% and 9.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ProQR (PRQR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of 12% and 16.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Bears are Losing Control Over ProQR (PRQR), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for ProQR (PRQR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
ProQR (PRQR) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ProQR (PRQR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of -15.38% and 69.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will ProQR (PRQR) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ProQR (PRQR) Plunges as Lead Drug Fails in Phase II/III Study
by Zacks Equity Research
ProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study.
Strength Seen in ProQR (PRQR): Can Its 7% Jump Turn into More Strength?
by Zacks Equity Research
ProQR (PRQR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.